Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
NF-kappaB Decoy
Sponsor
Anesiva, Inc.